Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Gapped Up | Strength | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -0.33% | |
Fell Below 50 DMA | Bearish | -0.33% |
Alert | Time |
---|---|
Fell Below Previous Day's Low | about 14 hours ago |
Gap Up Closed | about 15 hours ago |
60 Minute Opening Range Breakdown | about 15 hours ago |
Reversed from Up | about 15 hours ago |
20 DMA Resistance | about 15 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 218.88 |
52 Week Low | 141.975 |
Average Volume | 531,030 |
200-Day Moving Average | 169.47 |
50-Day Moving Average | 149.24 |
20-Day Moving Average | 148.05 |
10-Day Moving Average | 150.75 |
Average True Range | 4.13 |
RSI (14) | 45.36 |
ADX | 12.82 |
+DI | 18.29 |
-DI | 18.58 |
Chandelier Exit (Long, 3 ATRs) | 143.09 |
Chandelier Exit (Short, 3 ATRs) | 154.37 |
Upper Bollinger Bands | 154.72 |
Lower Bollinger Band | 141.38 |
Percent B (%b) | 0.45 |
BandWidth | 9.01 |
MACD Line | -0.04 |
MACD Signal Line | -0.13 |
MACD Histogram | 0.0957 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 153.67 | ||||
Resistance 3 (R3) | 154.22 | 152.69 | 152.63 | ||
Resistance 2 (R2) | 152.69 | 151.09 | 152.41 | 152.28 | |
Resistance 1 (R1) | 150.04 | 150.10 | 149.28 | 149.49 | 151.93 |
Pivot Point | 148.51 | 148.51 | 148.12 | 148.23 | 148.51 |
Support 1 (S1) | 145.86 | 146.91 | 145.10 | 145.31 | 142.87 |
Support 2 (S2) | 144.33 | 145.92 | 144.05 | 142.52 | |
Support 3 (S3) | 141.68 | 144.33 | 142.18 | ||
Support 4 (S4) | 141.13 |